Australia - English - Department of Health (Therapeutic Goods Administration)

hetero australia pty ltd - lamivudine, quantity: 300 mg; abacavir sulfate, quantity: 702.762 mg (equivalent: abacavir, qty 600 mg) - tablet - excipient ingredients: sodium starch glycollate; microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica; titanium dioxide; hypromellose; sunset yellow fcf; polysorbate 80; macrogol 400 - abalamid hetero 600/300 tablets are a combinaton of two nucleoside analogues (abacavir and lamivudine). abalamid hetero 600/300 is indicated in antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infection in adults and adolescents from 12 years of age.

Australia - English - Department of Health (Therapeutic Goods Administration)

hetero australia pty ltd - lamivudine, quantity: 300 mg; abacavir sulfate, quantity: 702.762 mg (equivalent: abacavir, qty 600 mg) - tablet - excipient ingredients: sodium starch glycollate; microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica; titanium dioxide; hypromellose; sunset yellow fcf; polysorbate 80; macrogol 400 - abalamid hetero 600/300 tablets are a combinaton of two nucleoside analogues (abacavir and lamivudine). abalamid hetero 600/300 is indicated in antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infection in adults and adolescents from 12 years of age.

Australia - English - Department of Health (Therapeutic Goods Administration)

hetero australia pty ltd - lamivudine, quantity: 300 mg; abacavir sulfate, quantity: 702.762 mg (equivalent: abacavir, qty 600 mg) - tablet - excipient ingredients: sodium starch glycollate; magnesium stearate; microcrystalline cellulose; colloidal anhydrous silica; titanium dioxide; hypromellose; sunset yellow fcf; polysorbate 80; macrogol 400 - abalamid hetero 600/300 tablets are a combinaton of two nucleoside analogues (abacavir and lamivudine). abalamid hetero 600/300 is indicated in antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infection in adults and adolescents from 12 years of age.

Australia - English - Department of Health (Therapeutic Goods Administration)

hetero australia pty ltd - valganciclovir, quantity: 450 mg - tablet, film coated - excipient ingredients: povidone; stearic acid; microcrystalline cellulose; crospovidone; titanium dioxide; hypromellose; polysorbate 80; iron oxide red; macrogol 400 - valganciclovir is indicated for the treatment of cytomegalovirus (cmv) retinitis in patients with acquired immunodeficiency syndrome (aids). valganciclovir is indicated for the prophylaxis of cmv infection and disease following solid organ transplantation in patients at risk of cmv disease.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

imtrade australia pty ltd - fluroxypyr as the methyl heptyl ester; liquid hydrocarbon - emulsifiable concentrate - fluroxypyr as the methyl heptyl ester pyridine-pyridinoxy active 200.0 g/l; liquid hydrocarbon solvent other 502.0 g/l - herbicide

Australia - English - Department of Health (Therapeutic Goods Administration)

hetero australia pty ltd - tenofovir disoproxil fumarate, quantity: 300 mg - tablet - excipient ingredients: microcrystalline cellulose; pregelatinised maize starch; croscarmellose sodium; lactose monohydrate; magnesium stearate; titanium dioxide; hypromellose; triacetin - tenofovir hetero in combination with other antiretroviral agents is indicated for the treatment of hiv-infected adults and paediatric patients 12 years of age and older.,tenofovir hetero is indicated for the treatment of chronic hepatitis b in adults (see clinical trials)..,tenofovir hetero is indicated for the treatment of chronic hepatitis b in paediatric patients 12 years of age and older with compensated liver disease and with evidence of immune active disease, i.e, active viral replication, persistently elevated serum alt levels or evidence of active inflammation.

Australia - English - Department of Health (Therapeutic Goods Administration)

hetero australia pty ltd - tenofovir disoproxil fumarate, quantity: 300 mg - tablet - excipient ingredients: microcrystalline cellulose; magnesium stearate; croscarmellose sodium; lactose monohydrate; pregelatinised maize starch; titanium dioxide; hypromellose; triacetin - tenofovir hetero in combination with other antiretroviral agents is indicated for the treatment of hiv-infected adults and paediatric patients 12 years of age and older.,tenofovir hetero is indicated for the treatment of chronic hepatitis b in adults (see clinical trials).,tenofovir hetero is indicated for the treatment of chronic hepatitis b in paediatric patients 12 years of age and older with compensated liver disease and with evidence of immune active disease, i.e, active viral replication, persistently elevated serum alt levels or evidence of active inflammation.

Australia - English - Department of Health (Therapeutic Goods Administration)

hetero australia pty ltd - bortezomib, quantity: 3.5 mg - injection, powder for - excipient ingredients: mannitol - bortezomib hetero in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated multiple myeloma who are not candidates for high dose chemotherapy. bortezomib hetero as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma. bortezomib hetero is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease. bortezomib hetero in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

hetero australia pty ltd - lamivudine, quantity: 300 mg; abacavir sulfate, quantity: 702.762 mg (equivalent: abacavir, qty 600 mg) - tablet - excipient ingredients: microcrystalline cellulose; sodium starch glycollate; magnesium stearate; colloidal anhydrous silica; titanium dioxide; hypromellose; sunset yellow fcf; polysorbate 80; macrogol 400 - abadine 600/300 tablets are a combinaton of two nucleoside analogues (abacavir and lamivudine). abadine 600/300 is indicated in antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infection in adults and adolescents from 12 years of age.

Australia - English - Department of Health (Therapeutic Goods Administration)

hetero australia pty ltd - lamivudine, quantity: 300 mg; abacavir sulfate, quantity: 702.762 mg (equivalent: abacavir, qty 600 mg) - tablet - excipient ingredients: sodium starch glycollate; microcrystalline cellulose; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; sunset yellow fcf; polysorbate 80; macrogol 400 - abadine 600/300 tablets are a combinaton of two nucleoside analogues (abacavir and lamivudine). abadine 600/300 is indicated in antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infection in adults and adolescents from 12 years of age.